Dyadic International Announces $2.9 Million Registered Direct Offering and Private Placement

Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has entered into definitive agreements with an institutional investor for a registered direct offering of 3,625,000 common shares and a concurrent private placement of warrants to purchase the same number of shares. The combined gross proceeds are expected to be approximately $2.9 million, with the common shares priced at $0.795 each and warrants at $0.005 each, carrying an exercise price of $0.84 per share.

The transactions, which are expected to close on or about Aug. 14, 2026, are subject to customary closing conditions. Dyadic intends to use the net proceeds, along with its existing cash, cash equivalents, restricted cash, and investment-grade securities, for working capital and general corporate purposes. Aegis Capital Corp. is serving as the exclusive placement agent for the offerings.

This financing comes at a critical time for Dyadic as it continues to advance its proprietary Dapibus™ and C1 expression systems, which are designed to enable rapid, cost-effective, and flexible manufacturing of high-value proteins. The company's focus is on developing and commercializing scalable, non-animal protein production platforms to address growing global demand across the life sciences, food and nutrition, and bio-industrial markets. By leveraging these technologies, Dyadic aims to help customers create more efficient, scalable, and sustainable products.

The announcement underscores the company's commitment to strengthening its financial position to support ongoing research and development initiatives. The additional capital is expected to provide Dyadic with the flexibility to pursue its strategic objectives and potentially accelerate the commercialization of its protein production platforms. This move reflects a broader industry trend where biotechnology companies are seeking non-dilutive and strategic funding to sustain innovation and market expansion.

For investors, this offering represents an opportunity to participate in Dyadic's growth trajectory, albeit with the inherent risks associated with equity offerings and warrant exercises. The pricing of the offering, which includes a warrant exercise price slightly above the share price, suggests a measured approach to balancing investor interests with the company's capital needs.

Dyadic's technology has the potential to disrupt traditional protein production methods by offering a more sustainable and efficient alternative to animal-derived proteins. The company's platforms are designed to meet the increasing demand for environmentally friendly and ethically produced proteins, which is a significant driver in the life sciences and food industries. With this new funding, Dyadic is well-positioned to continue its mission of delivering innovative bioprocessing solutions.

As the biotech sector continues to evolve, Dyadic's focus on scalability and sustainability aligns with global trends toward greener and more efficient manufacturing processes. The successful completion of this offering will not only provide immediate working capital but also signal investor confidence in the company's long-term strategy. The proceeds are expected to support Dyadic's operational needs, including research and development, intellectual property protection, and potential strategic partnerships.

In summary, Dyadic International's latest financing move is a strategic step to bolster its financial resources and advance its innovative protein production technologies. The company remains dedicated to creating value for its shareholders while addressing critical global challenges in protein supply and sustainability.